FDA Postmarketing Studies Web Site Includes Schering, GSK Commitments
This article was originally published in The Tan Sheet
Executive Summary
FDA's 1new postmarketing Web site notes Schering-Plough has agreed to study the efficacy of Lotrimin Ultra 1% cream (butenafine HCl 1%) in children as one of its Phase IV commitments